


**STEREOCHEMISTRY ABSTRACTS**

H. S. Bevinakatti, A. A. Banerji, R. V.,  
Newadkar, A. A. Mokashi.

Tetrahedron: Asymmetry 1992, 3, 1505



E.e % 69 (by chiral HPLC)

Source of chirality : Lipase Catalysed enantioselective ring opening of 2 Phenyl-Oxazoline-5 Ones


Absolute Configuration : S

$C_{20}H_{23}NO_3$

Butyl N-benzoyl phenyl alaninate

H. S. Bevinakatti, A. A. Banerji, R. V.,  
Newadkar, A. A. Mokashi.

Tetrahedron: Asymmetry 1992, 3, 1505



E.e % 47 (by chiral HPLC)

Source of chirality : Lipase Catalysed enantioselective ring opening of 2 Phenyl-Oxazoline-5 Ones


Absolute Configuration : S

$C_{14}H_{19}NO_3$

Butyl N-benzoyl alaninate

H. S. Bevinakatti, A. A. Banerji, R. V.,  
Newadkar, A. A. Mokashi.

Tetrahedron: Asymmetry 1992, 3, 1505



E.e % 66 (by chiral HPLC)

Source of chirality : Lipase Catalysed enantioselective ring opening of 2 Phenyl-Oxazoline-5 Ones


Absolute Configuration : S

$C_{17}H_{25}NO_3$

Butyl N-benzoyl leucinate

H. S. Bevinakatti, A. A. Banerji, R. V.,  
Newadkar, A. A. Mokashi.

Tetrahedron: Asymmetry 1992, 3, 1505




E.e % 43 (by chiral HPLC)

Source of chirality : Lipase Catalysed enantioselective ring opening of 2 Phenyl-Oxazoline-5 Ones

Absolute Configuration : S

$C_{16}H_{23}NO_3$


Butyl N-benzoyl norvalinate



(2S,5R)-(-)-1-Benzylxyhepta-3,4-dien-2-ol


E.e. = 89% ( GLC and  $^1H$ -NMR of the acetate )  
 $[\alpha]_D^{25} -22.8$  (  $c = 0.35$ ,  $CHCl_3$  )

Source of Chirality : natural and asymm. synth.  
 Absolute Configuration : 2S, 5R




(2R,5S)-(+)-1-Benzylxynona-3,4-dien-2-ol

E.e. = >99% ( GLC and  $^1H$ -NMR of the acetate )  
 $[\alpha]_D^{25} +19.7$  (  $c = 0.33$ ,  $CHCl_3$  )  
 Source of Chirality: natural and asymm. synth.  
 Absolute Configuration : 2R, 5S




(3R)-1-O-t-Butyldiphenylsilyl-3,4-O-isopropylidene-D-erythrulose

$[\alpha]_D^{23} +18$  (  $c 3.8$ ,  $CHCl_3$  )  
 Source of chirality - D-isoascorbic acid  
 Absolute configuration: 3R



(2R,3S)-2-Methyl-3,4-O-isopropylidenebutane-1,2,3,4-tetraol

$[\alpha]_D^{23} -67$  (  $c 3$ ,  $CHCl_3$  )  
 Source of chirality. L-ascorbic acid  
 Absolute configuration. 2R, 3S (assignment via chemical correlation)



 $C_{19}H_{24}O_4$ 

(2R,3S)-2-Methyl-1,2-di-O-benzylbutane-1,2,3,4-tetraol

 $[\alpha]_D^{23} +6.4 \quad (c\ 3.1,\ CHCl_3)$ 

Source of chirality: L-ascorbic acid

Absolute configuration: 2R, 3S (assignment via chemical correlation)



 $C_{19}H_{22}O_2$ 

(2S)-2-Methyl-1,2-di-O-benzylbut-3-ene-1,2-diol

 $[\alpha]_D^{23} -7.1 \quad (c\ 3.4,\ CHCl_3)$ 

Source of chirality: L-ascorbic acid

Absolute configuration: 2S (assignment via chemical correlation)




E.e.&gt; 96% (inferred from e.e. of precursor)

 $[\alpha]_D +157 \quad (c\ 0.7,\ acetone)$ 

Source of chirality: synthesis from (-)-menthyl (S)<sub>S</sub>-p-toluenesulfinate

Absolute configuration: (S)<sub>S</sub>

(+)-(S)- $\alpha$ -Diethoxyphosphorylvinyl p-tolyl sulfoxide



E.e.&gt; 96% (inferred from e.e. of precursor)


 $[\alpha]_D -50.8 \quad (c\ 0.7,\ acetone)$ 

Source of chirality: synthesis from (-)-menthyl

(S)<sub>S</sub>-p-toluenesulfinate

Absolute configuration: (S)<sub>S</sub>

(-)-p-Tolyl 3H-pyrrolizine-2-sulfoxide




E.e. &gt;96%

 $[\alpha]_D^{25} +14$  (c 0.25, acetone)


Source of chirality: asymm. synth. (Diels-Alder)

Diethyl bicyclo[2.2.1] hept-2,5-diene-phosphonate

E.e. = 79% [by  $^1H$ -NMR of the MTPA ester derivative and by comparison with the sample obtained from optically pure ethyl (*S*)-3-hydroxybutyrate] $[\alpha]_D^{25} = -27.5$  (c 0.68,  $CHCl_3$ )


Source of chirality: Enzymatic aminolysis

Absolute configuration: R

E.e. = 79% [by  $^1H$ -NMR of the MTPA ester derivative] $[\alpha]_D^{25} = +12.2$  (c 0.99,  $CHCl_3$ )Source of chirality: (*R*)-*N*-Butyl-3-hydroxybutyramide,


79% e.e.

Absolute configuration: R

E.e. = 75% [by  $^1H$ -NMR of the MTPA ester derivative and by comparison with the sample obtained from optically pure ethyl (*S*)-3-hydroxybutyrate] $[\alpha]_D^{25} = -30.6$  (c 0.75,  $CHCl_3$ )

Source of chirality: Enzymatic aminolysis


Absolute configuration: R



(R)-1-Propylamino-3-hydroxybutane


E.e. = 75% [by  $^1H$ -NMR of the MTPA ester derivative] $[\alpha]_D^{22} = +14.2$  (c 0.89,  $CHCl_3$ )Source of chirality: (*R*)-*N*-Allyl-3-hydroxybutyramide,  
75% e.e.

Absolute configuration: R

(R)-*N*-Benzyl-3-hydroxybutyramideE.e. >99% [by  $^1H$ -NMR of the MTPA ester derivative and  
by comparison with the sample obtained from optically pure  
ethyl (*S*)-3-hydroxybutyrate] $[\alpha]_D^{22} = -33.8$  (c 0.96,  $CHCl_3$ )

Source of chirality: Enzymatic aminolysis



Absolute configuration: R



(R)-1-Benzylamino-3-hydroxybutane

E.e. >99% [by  $^1H$ -NMR of the MTPA ester derivative] $[\alpha]_D^{22} = +16.3$  (c 0.90,  $CHCl_3$ )Source of chirality: (*R*)-*N*-Benzyl-3-hydroxybutyramide,  
>99% e.e.

Absolute configuration: R




9-hydroxy-(E)-2-decanoic acid (9-HDA)

E.e. = 100% [by  $^1H$  NMR in presence of chiral shift reagent] $[\alpha]_D = -5.42$  (C 1.4, EtOH)

Source of Chirality: microbial reduction

Absolute Configuration: R




2-Methylene-3-[((E)-3'-cyclohexyl-3-(*t*-butyldimethylsilyl)oxy-1'-propenyl]-4-(*t*-butyldimethylsilyl)oxycyclopent-1-one

Absolute configuration 3*R*, 4*R*, 3'S

$[\alpha]_D^{33} -27.6 (c = 1.59, \text{CHCl}_3)$

Prepared from homochiral

(*R*)-2-(diethylamino)methyl-4-(*t*-butyl dimethylsilyl)oxycyclopent-2-en-1-one



1,2,3,16,17,18,19,20-Octanor-4-hydroxy-15-cyclohexyl prostaglandin  $F_{2\alpha}$  11,15-bis(*t*-butyl-dimethylsilyl) ether


Absolute configuration 8*R*, 9*S*, 11*R*,

12*R*, 15*S* (PG-numbering)

$[\alpha]_D^{26} -5.0 (c = 1.79, \text{CHCl}_3)$

Prepared from homochiral

(*R*)-2-(diethylamino)methyl-4-(*t*-butyl dimethylsilyl)oxycyclopent-2-en-1-one



16,17,18,19,20-Pantanor-3-oxo-15-cyclohexyl prostaglandin  $F_{2\alpha}$  *t*-butyl ester 11,15-bis(*t*-butyl-dimethylsilyl) ether


Absolute configuration 8*R*, 9*S*, 11*R*,

12*R*, 15*S* (PG-numbering)

$[\alpha]_D^{26} +11.8 (c = 1.06, \text{CHCl}_3)$

Prepared from homochiral

(*R*)-2-(diethylamino)methyl-4-(*t*-butyl dimethylsilyl)oxycyclopent-2-en-1-one




E.e. = 93 % (by chiral GLC)

$[\alpha]_D^{25} = -14 (c 0.8, \text{CH}_2\text{Cl}_2)$

Source of chirality: PPL

catalysed resolution


Absolute configuration: 2*S*, 3*R*

 $C_{19}H_{28}O_2$  $R = 8\text{-(5'-Methoxy-2'-methylphenyl)-8-methyldecahydro-1-naphthalenyl}$  $[\alpha]_D^{20} = -35.69 \text{ (c } 0.51, \text{EtOH)}$ 


Source of chirality: synthesis from podocarpic acid

Absolute configuration  $1R,4aS,8S,8aS$   
(by 300MHz n.m.r.) $R = 8\text{-(5'-Methoxy-2'-methylphenyl)-8-methyldecahydronaphthalen-1'-yl}$  $C_{27}H_{36}O_3$  $8\text{-(5'-Methoxy-2'-methylphenyl)-8'-methyldecahydronaphthalen-1'-yl endo-2-bicyclo[2.2.1]hept-5-ene carboxylate}$  $[\alpha]_D^{25} = +30.90 \text{ (c } 0.61, \text{CHCl}_3)$ 

Source of chirality: asymmetric synthesis

Absolute Configuration  $1R,4a'S,8'S,8a'S,2R$   
(by correlation with an optically active sample) $R = 8\text{-(5'-Methoxy-2'-methylphenyl)-8-methyldecahydronaphthalen-1'-yl}$  $C_{27}H_{34}O_4$  $8\text{-(5'-Methoxy-2'-methylphenyl)-8'-methyldecahydronaphthalen-1'-yl 2-hydroxyphenylacetate}$  $[\alpha]_D^{25} = -8.0 \text{ (c } 0.25, \text{CHCl}_3)$ 

Source of chirality: asymmetric synthesis


Absolute Configuration  $1R,4a'S,8'S,8a'S,2R$   
(by correlation with (R)-2([N-isopropyl]-amino)-1-phenylethanol) $[\alpha]_D^{25} = -35.9 \text{ (c=1, CH}_3\text{OH)}$ 

Source of chirality: D-glutamic acid

Absolute configuration: 2R

 $C_7H_{11}NO_3$ 

(R)-(-)-tetrahydro-N,N-dimethyl-5-oxo-2-furancarboxamid



E.e. = >99% (nmr with (S)-(+)-1-(9-anthryl)-2,2,2-trifluorethanol)


$[\alpha]_D^{23} = +62.7$  ( $c=1$ , CH<sub>3</sub>OH)

Source of chirality: L-glutamic acid

Absolute configuration: 5S

C<sub>7</sub>H<sub>14</sub>BrNO<sub>2</sub>

(S)-(+)-5-dimethylaminomethyl-4,5-dihydro-2(3H)furanone, hydrobromide




$[\alpha]_D^{20} = +49.4$  ( $c=1$ , CH<sub>3</sub>OH)

Source of chirality: L-glutamic acid

Absolute configuration: 5S

C<sub>8</sub>H<sub>16</sub>BrNO<sub>2</sub>

(S)-(+)-5-dimethylaminomethyl-4,5-dihydro-2(3H)furanone, methobromide




E.e. = 78%

$[\alpha]_D^{23} = -55.0$  ( $c = 1.1$ , CHCl<sub>3</sub>)

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 2R

(R)-2-phenylpropionamide





E.e. = 65%

$[\alpha]_D^{23} = +43.0$  ( $c = 1.98$ , CHCl<sub>3</sub>)

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 2S

(S)-2-phenylpropionic acid





(R)-2-phenylbutyramide



E.e. = &gt;98%

 $[\alpha]_D^{26} = -79.5$  ( $c = 1$ ,  $CHCl_3$ )

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 2*R*

(S)-2-phenylbutanoic acid




(R)-2-(4'-iso-butylphenyl)propionamide

E.e. = 26%

 $[\alpha]_D^{28} = -9.1$  ( $c = 1.44$ ,  $CHCl_3$ )

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 2*R*



(R)-2-(4'-iso-butylphenyl)propionic acid

E.e. = 35%

 $[\alpha]_D^{29} = -14.7$  ( $c = 1.28$ ,  $EtOH$ )

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 2*R*



(S)-3-O-(Benzyl)-4-cyanobutanoic acid



E.e. = 83%

 $[\alpha]_D^{27} = +9.6$  ( $c = 3.4$ ,  $\text{CHCl}_3$ )

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 3*S*

(assigned by comparison with authentic sample prepared from (S)-(-)-methyl-3-hydroxy-4-bromobutanoic acid)



E.e. = 84%


 $[\alpha]_D^{24} = +32.4$  ( $c = 1.08$ ,  $\text{CHCl}_3$ )

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 3*S*

(assigned by comparison with literature data)

(S)-3-O-(Benzoyl)-4-cyanobutanoic acid



E.e. = 22%


 $[\alpha]_D = 0.0$  ( $c = 1.0$ ,  $\text{EtOH}$ )

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 3*S*

(assigned by comparison with literature data)

(S)-3-Hydroxy-4-cyanobutanoic acid



E.e. = 61%


 $[\alpha]_D^{25} = -2.8$  ( $c = 1.21$ ,  $\text{CHCl}_3$ )

Source of chirality: enzyme nitrile hydrolysis

Absolute configuration: 3*S*

(assigned by comparison with literature data)


(S)-3-O-(methoxyethoxymethyl)-4-cyanobutanoic acid



97% ee [by HPLC of 3,5-dinitrobenzoate]  
source of chirality (S)-Lactic acid  
 $[\alpha]_D^{23} -96$  (*c* 1.5, CHCl<sub>3</sub>)

 $C_{14}H_{14}O_3$ 


(S)-2-Hydroxy-1-(6-methoxy-2-naphthyl)-1-propanone



97% ee by chiral phase HPLC  
source of chirality (S)-Lactic acid  
 $[\alpha]_D^{23} +76.5$

 $C_{15}H_{16}O_3$ 

Methyl (S)-2-(6-methoxy-2-naphthyl)propionate




E.e. = 100%

 $[\alpha]_D = -121.6$  (*c* 1.028, CHCl<sub>3</sub>)

Source of chirality: (1R,2S)-(-)-Ephedrine

 $C_{14}H_{16}N_2O_2$ 

(4R,5S)-1,5-dimethyl-4-phenyl-3-prop-2'-enoylimidazolidin-2-one




E.e. = 100%

 $[\alpha]_D = -104.3$  (*c* 0.67, CHCl<sub>3</sub>)

Source of chirality: (1R,2S)-(-)-Ephedrine

 $C_{15}H_{18}N_2O_2$ 

(4R,5S)-1,5-dimethyl-4-phenyl-3-but-2'-enoylimidazolidin-2-one




E.e. = 100%

 $[\alpha]_D = -43.64$  (c 0.97, CHCl<sub>3</sub>)

Source of chirality: (1R,2S)-(-)-Ephedrine

C14H22N2O2

(4R,5S)-4-cyclohexyl-1,5-dimethyl-3-prop-2'-enoylimidazolidin-2-one




E.e. = 100%

 $[\alpha]_D = -52.89$  (c 1.68, CHCl<sub>3</sub>)

Source of chirality: (1R,2S)-(-)-Ephedrine

C15H24N2O2


(4R,5S)-4-cyclohexyl-1,5-dimethyl-3-but-2'-enoylimidazolidin-2-one



E.e. ≥ 96% (by n.m.r.)

 $[\alpha]_D = -221.56$  (c 1.90, CHCl<sub>3</sub>)Source of chirality: Natural and asymm. synthesis  
(D-A cycloaddition)C19H22N2O2


(4R,5S)-3-((3'R,4'R,6'R)bicyclo[2.2.1]heptene-4'-carbonyl)-1,5-dimethyl-4-phenylimidazolidin-2-one



E.e. ≥ 99% (by n.m.r.)

 $[\alpha]_D = -222.08$  (c 0.40, CHCl<sub>3</sub>)Source of chirality: Natural and asymm. synthesis  
(D-A cycloaddition)C20H24N2O2


(4R,5S)-3-((3'R,4'R,5'S,6'S)-5'-methylbicyclo[2.2.1]heptene-4'-carbonyl)-1,5-dimethyl-4-phenylimidazolidin-2-one



ee. 100% (by n.m.r.)

 $[\alpha]_D = -77.84$  (c 1.07,  $\text{CHCl}_3$ )Source of chirality: Natural and asymm. synth  
(D-A cycloaddition)


(4R,5S)-3-((3'R,4'R,6'R)-bicyclo[2.2.1]heptene-4'-carbonyl)-4-cyclohexyl-1,5-dimethyl-imidazolidin-2-one



E.e. 100% (by n.m.r.)

 $[\alpha]_D = -113.36$  (c 1.27,  $\text{CHCl}_3$ )Source of chirality: Natural and asymm. synth  
(D-A cycloaddition)


(4R,5S)-3-((3'R,4'R,5'S,6'S)-5'-methylbicyclo[2.2.1]heptene-4'-carbonyl)-4-cyclohexyl-1,5-dimethylimidazolidin-2-one



E.e. ≥ 99 % [by comparison to lit. value]


 $[\alpha]_D^{20} = -15.3$  (c = 2, dioxane)Source of chirality: optical resolution by brucine  
Absolute configuration: 11S,12S  
M.p. 220 °C

9,10-Dihydro-9,10-ethanoanthracen-11,12-dicarboxylic acid

 $[\alpha]_D^{25} = -23$  (c 0.28,  $\text{CHCl}_3$ )Source of chirality: D-(+)-arabinose, (+)-menthol  
Absolute configuration: 3S, 4R, 5S, 6S


2-Deoxy-2-hydroxymethyl-L-gluco-heptitol heptaacetate

A. Saba\*, V. Adovasio and M. Nardelli



$[\alpha]_D^{25} = +29$  (c 0.61,  $\text{CHCl}_3$ )  
Source of chirality: L-(+)-arabinose, (+)-menthol and  
(-)menthol  
Absolute configuration 3S, 4S, 5R, 6R

2-Deoxy-2-hydroxymethyl-D-manno-heptitol heptaacetate


J.Irurre, C.Alonso-Alija, J.F.Piniella,  
A.Alvarez-Larena

E.e.  $\geq 98\%$  (from asymmetric synthesis results)  
 $[\alpha]_D^{20} = +54.2$  (c 0.964,  $\text{CHCl}_3$ )

(4R,5R)-2,2-Diphenyl-4,5-dimethoxycarbonyl-1,3-dioxolane

Source of chirality: (+)-dimethyl-L-tartrate

Absolute configuration 4R,5R


J.Irurre, C.Alonso-Alija, J.F.Piniella,  
A.Alvarez-Larena

E.e.  $\geq 98\%$  (from asymmetric synthesis results)  
 $[\alpha]_D^{20} = +187.7$  (c 0.505,  $\text{CHCl}_3$ )

Source of chirality: (+)-dimethyl-L-tartrate

Absolute configuration 4R,5R

A. Solladié-Cavallo, A. Adib, M. Schmitt, J. Fischer, A. DeCian



Source of chirality: (+) pulegone  
Absolute configuration: 3S7R9R10S  
determined from 2D  $^1\text{H}$  NMR and X-ray  
 $[\alpha]_D = -172$  (1.02, acetone)  
(the benzyl group on S is axial)

Hexahydro-4,4,7-trimethyl-3-benzyl-1,3-benzoxathianium  
perchlorate